
Microbot Medical (MBOT) Stock Forecast & Price Target
Microbot Medical (MBOT) Analyst Ratings
Bulls say
Microbot Medical is entering an exciting growth phase as they enter full market release (FMR) at the SIR annual scientific meeting this week, with a limited market release (LMR) that showed strong customer adoption and a shorter sales cycle compared to traditional surgical robots. With a targeted market of 2.5 million peripheral endovascular procedures in the US annually and an expanding sales footprint, we expect to see meaningful topline sales ramp-up during the remainder of 2026. With their innovative and unique fully disposable robotic system, proven successful in multiple procedures, and with Emory Healthcare's adoption, we anticipate favorable adoption by physicians and multi-billion-dollar revenues by FY29.
Bears say
Microbot Medical is positioning itself in the emerging market of robotic endoluminal surgery devices, but there are several fundamental risks to consider. These include slower-than-expected adoption, potential delays in securing international regulatory approvals, lack of profitability in the near term, and potential setbacks in expanding into neuro and cardio cases. Additionally, the lack of a dedicated reimbursement code for the company's LIBERTY system could present a barrier to adoption, despite the potential for attractive reimbursements for procedures enabled by the system.
This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.
Microbot Medical (MBOT) Analyst Forecast & Price Prediction
Start investing in Microbot Medical (MBOT)
Order type
Buy in
Order amount
Est. shares
0 shares